 Schrodinger Inc NASDAQ:SDGR reported downbeat third-quarter results, mainly due to lower-than-expected drug discovery revenues, according to BofA Securities. The Schrodinger Analyst: Michael Ryskin downgraded Schrodinger from Buy to Neutral and lowered the price target from 80 to 52. 